Where is Kyrix located?

Kyrix is headquartered in Edinburgh, United Kingdom.

Is Kyrix a funded company?

Kyrix is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Kyrix rank among its competitors?

Kyrix ranks 9th amongst 9 active competitors, of which 5 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was ImpriMed, which secured $23.2M in Nov, 2023.

Who are the top competitors of Kyrix?

Kyrix's top competitors include ImpriMed, QBiotics and VetDC. Among them, ImpriMed secured the most recent funding round in November, 2023.

Kyrix - 2026 Company Profile & Competitors

Company Details

Developer of pharmaceutical treatments for managing cancer in domestic animals. These medications aim to slow disease progression while maintaining quality of life for the patient. The drugs are designed for administration by owners within a home environment, removing the requirement for specialized safety precautions typically associated with traditional oncology therapies. The development process focuses on efficacy and safety for the treatment of canine patients.

Key Metrics

Founded Year

2023

Location

Edinburgh, United Kingdom

Stage

Unfunded

Ranked

9^th among 9 active competitors

Similar Companies

ImpriMed & 8 more

View Kyrix's full profile

Kyrix has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kyrix include ImpriMed, QBiotics and VetDC. Here is the list of Top 10 competitors of Kyrix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ImpriMed 2017, Palo Alto (United States), Series A	Provider of precision medicines for veterinary cancer	$34.9M	SK Telecom, SBVA & 26 others	60/100
2nd	QBiotics 2000, Brisbane (Australia), Series C	Developer of small molecules discovered from the plant extracts	$98.1M	TDM Growth Partners, WG Partners	53/100
3rd	VetDC 2010, Fort Collins (United States), Series A	Developing advanced cancer treatments for pets, enhancing their quality of life	$5.51M	Keiretsu Forum, Innosphere & 1 others	36/100
4th	Animal Life Sciences 2018, New York City (United States), Seed	Developer of pet food, supplements and therapeutics to treat cancer in animals	$199K	-	26/100
5th	Vetco Pharmaceuticals 2012, Sanchong (Taiwan), Unfunded	Provider of pharmaceutical products for treating cancer in animals	-	-	24/100
6th	CanFel Therapeutics 1999, Torrance (United States), Funding Raised	Developer of therapeutics for treating cancer in animals	-	Springboard Enterprises	23/100
7th	BioTesserae 2022, Corvallis (United States), Seed	Company developing nanobody-based therapies for canine cancer treatment for pet health	$100K	Expert DOJO	22/100
8th	MT3 2018, Minato (Japan), Funding Raised	Developer of therapeutics for cancer treatment in animals	-	Miyako Capital	21/100
9th	Kyrix 2023, Edinburgh (United Kingdom), Unfunded	Developer of pharmaceutical treatments for managing cancer in domestic animals	-	-	16/100
10th	Blue Horizon Biotech 2020, United States, Deadpooled	Developer of veterinary therapeutics for the treatment of cancer	-	-	15/100